Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Mult Scler Relat Disord. 2021 Oct;55:103189. doi: 10.1016/j.msard.2021.103189. Epub 2021 Aug 2.
The COVID-19 vaccines are currently recommended for people with rare neuroimmunological diseases such as neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease (MOGAD), and transverse myelitis. However, the safety profile of the vaccines in this population is uncertain.
To report real-world safety data of the COVID-19 vaccines in persons with rare neuroimmunological diseases.
An anonymous survey was distributed to patients recruited on social media. Participants answered general demographic and disease-related questions, and specific questions about their experiences with the COVID-19 vaccines.
438 participants completed the questionnaire. The median age was 51 (range 18-82 years); 366 were female (83.6%); 102 (23.3%) had associated comorbidities, and 354 (80.1%) were treated with immunotherapies. 242 participants (55.3%) reported a diagnosis of NMOSD; 99 (22.6%) had MOGAD; 79 (18%) had transverse myelitis. 239 participants (66.2%) were younger than 55 years of age. 138 participants (31.5%) reported earlyadverse events. Of these, 93 (67.4%) were < 55 years old, and 45 (32.6%) were > 55 years old (p=0.0086). The most common adverse events were local reactions, including pain, redness, and swelling at the injection site, reported by 155 participants (35.4%). 73 participants (16.7%) reported new or worsening neurological symptoms following the vaccination. Most symptoms occurred within the first week after vaccination and resolved within three days.
This survey indicates an overall favorable safety and tolerability profile of the COVID-19 vaccines among persons with rare neuroimmunological diseases. Longer-term studies are warranted to confirm these data.
目前建议患有神经免疫性疾病（如视神经脊髓炎谱系疾病[NMOSD]、MOG 抗体病[MOGAD]和横贯性脊髓炎）等罕见疾病的人群接种 COVID-19 疫苗。然而，该人群接种疫苗的安全性数据尚不确定。
报告 COVID-19 疫苗在患有罕见神经免疫性疾病的人群中的真实世界安全性数据。
我们向通过社交媒体招募的患者分发了匿名调查问卷。参与者回答了一般人口统计学和疾病相关问题，以及他们接种 COVID-19 疫苗的具体经历。
438 名参与者完成了问卷。中位年龄为 51 岁（范围 18-82 岁）；366 名女性（83.6%）；102 名（23.3%）合并有其他疾病，354 名（80.1%）接受免疫治疗。242 名（55.3%）参与者报告诊断为 NMOSD；99 名（22.6%）患有 MOGAD；79 名（18%）患有横贯性脊髓炎。239 名（66.2%）参与者年龄小于 55 岁。138 名（31.5%）参与者报告出现早期不良反应。其中，93 名（67.4%）年龄小于 55 岁，45 名（32.6%）年龄大于 55 岁（p=0.0086）。最常见的不良反应是局部反应，包括注射部位疼痛、发红和肿胀，155 名（35.4%）参与者报告了这些反应。73 名（16.7%）参与者在接种疫苗后出现新的或加重的神经症状。大多数症状发生在接种疫苗后第一周内，并且在三天内得到缓解。
本调查表明 COVID-19 疫苗在患有罕见神经免疫性疾病的人群中总体具有良好的安全性和耐受性。需要进行更长时间的研究来证实这些数据。
